Pyxis Oncology

Update in progress

PYXS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Pyxis Oncology, Inc. is a clinical-stage company developing therapies for solid tumors. Its lead ADC, PYX-201, is in Phase 1 for relapsed or refractory solid tumors. Other programs include PYX-102, a KLRG1-targeting immunotherapy; PYX-106, a fully human IgG1 anti-Siglec-15 antibody in Phase 1; and PYX-107, a CD40 agonist in Phase 2. The company has licensing deals with Pfizer for ADCs and with Biosion USA for PYX-106. Headquartered in Boston, founded 2018.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive